Similarly to pertuzumab, lapatinib has also been used in combination with trastuzumab to treat Her2-positive breast tumors; an enhanced apoptosis-induction in vitro was observed [99,101,102]. This evidence concerns the gene ERBB2 and breast neoplasm.